Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 14/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.81 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.81 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.81 |
| ▸ | HTR1A | P08908 | 1/20 | 0.81 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.81 |
| ▸ | MC4R | P32245 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5858026 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| Rofecoxib SCHEMBL4434618 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| Rofecoxib SCHEMBL3050 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| Rofecoxib SCHEMBL14163950 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| Rofecoxib SCHEMBL28953295 | 0.88 | PTGS2 (0.97) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| Rofecoxib SCHEMBL6598209 | 0.88 | PTGS2 (0.97) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| Rofecoxib SCHEMBL7860859 | 0.88 | PTGS2 (0.97) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| SCHEMBL3873376 | 0.87 | PTGS2 (1.00) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| SCHEMBL6179919 | 0.87 | PTGS2 (0.78) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| SCHEMBL3249223 | 0.87 | PTGS2 (0.78) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119143640-A | Preparation method of novel COX-2 inhibitor and intermediate thereof | 北京阳光诺和药物研究股份有限公司 | 2024-12-17 | — | — | CN | claimed |
| CN-119143640-A | Preparation method of novel COX-2 inhibitor and intermediate thereof | 北京阳光诺和药物研究股份有限公司 | 2024-12-17 | — | — | CN | disclosed |
| CN-118994063-A | Novel method for synthesizing eremophilne intermediate | 上海博悦生物科技有限公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118702608-A | Novel synthesis method of eremophilone | 重庆圣华曦药业股份有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-110386891-B | Preparation method of erexib | 新发药业有限公司 | 2020-07-17 | — | — | CN | disclosed |
| CN-108864003-B | Preparation method of dapoxib intermediate and dapoxib | 江苏美迪克化学品有限公司 | 2020-06-16 | — | — | CN | disclosed |
| US-7645747-B2 | Improved pharmacokinetic properties, oral bioavailability; side effect reduction | GILEAD SCIENCES, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | CANNIZZARO CARINA | 2009-10-01 | — | — | US | disclosed |
| US-7432261-B2 | Anti-inflammatory phosphonate compounds | GILEAD SCIENCES, INC. (US) | 2008-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | PHOSPHO1, TNF, PTGES | PTGS2 13/4885PTGS1 6/4885ABCB11 2592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.